trending Market Intelligence /marketintelligence/en/news-insights/trending/ZzxHUOA4b7yKIH6BrGIq3A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

AstraZeneca sees no risks after disclosure of falsified cancer drug data

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca sees no risks after disclosure of falsified cancer drug data

AstraZeneca PLC said a preclinical data set from one early-stage study supporting the development of acalabrutinib for cancer were falsified, adding that there are no risks for patients.

The company said a former Acerta Pharma employee acted alone to falsify the preclinical data set provided through external collaborations, but the "isolated issue" had no effect on the integrity of the drug.

The "data integrity issue" pre-dated AstraZeneca's $4 billion investment in Acerta Pharma in 2015.

In August, the U.S. Food and Drug Administration granted breakthrough therapy designation to acalabrutinib to treat patients with mantle cell lymphoma, a rare type of blood cancer.